Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.44 |
| ▸ | EPOR | P19235 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26803753 | 1.00 | GLP1R (0.52) | GLP1RFOLH1EPOREPHX2ADRA1A | |
| SCHEMBL26803757 | 0.92 | GLP1R (0.65) | GLP1RFOLH1 | |
| SCHEMBL19057808 | 0.92 | GLP1R (0.65) | GLP1RFOLH1 | |
| SCHEMBL19057810 | 0.91 | GLP1R (0.57) | GLP1REPHX2 | |
| SCHEMBL26803766 | 0.91 | GLP1R (0.57) | GLP1REPHX2 | |
| SCHEMBL11920365 | 0.91 | GLP1R (0.57) | GLP1RFOLH1EPOREPHX2 | |
| SCHEMBL11920370 | 0.91 | GLP1R (0.57) | GLP1RFOLH1EPOREPHX2 | |
| SCHEMBL14118023 | 0.91 | GLP1R (0.57) | GLP1RFOLH1EPOREPHX2 | |
| SCHEMBL11920369 | 0.91 | GLP1R (0.57) | GLP1RFOLH1EPOREPHX2 | |
| SCHEMBL23544197 | 0.90 | GLP1R (0.50) | GLP1RFOLH1EPOREPHX2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20170183383-A1 | OXYNTOMODULIN ANALOGUE | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | GLP1R, GCGR, GIPR | GLP1R 1/4885FOLH1 513/4885EPOR 786/4885 |
| US-20170183383-A1 | OXYNTOMODULIN ANALOGUE | GCGR, GLP1R, GIPR | GLP1R 2/4885FOLH1 536/4885EPOR 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.